1 / 4

CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina

CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina.

amora
Télécharger la présentation

CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAPTURE:C7E3FabAnti-PlateletTherapy in Unstable REfractory Angina • Study Population: Patients with chest pain at rest and ECG signs of UA (NQMI excluded) proven refractory to 2-48 hours of heparin and nitroglycerin and determined eligible via diagnostic catheterization for PCI within 18-24 hours • Dosing arms: ASA + standard-dose, weight-adjusted heparin - abciximab 0.25 mg/kg bolus + 10 µg/min infusion for 18-24 hours pre-PCI and 1 hour post-PCI (n=630) - placebo (n=635) • Primary endpoint: Death, MI, or urgent repeat intervention at 30 days The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

  2. CAPTUREStudy design heparin + nitroglycerin ASA + heparin + abciximab Diagnostic catheterization confirming eligibility for PCI PCI • Diagnosis of refractory UA • Chest pain with ECG signs of ischemia with heparin + nitroglycerin • Diagnosis of UA • Chest pain with ECG signs of ischemia (non-Q-wave MI excluded) 2 - 48 hours 18 - 24 hours 1 hour pre-PCI post-PCI The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

  3. CAPTUREEfficacy results summary Endpoint Death, MI, or urgent repeat interventionDeath, MI, or anyrevascularizationDeathMIUrgent repeat intervention Anyrevascularization Time30 days 6 months30 days6 months Pre-PCI30 days6 months30 days6 months Placebo(n=635) 15.9% 30.8%1.3%2.2% 2.1%8.2%9.3% 10.9%24.9% Abciximab (n=630) 11.3% 31.0%1.0%2.8% 0.6%4.1%6.6% 7.8%25.4% P value vsplacebo 0.012 nsnsns0.0290.002ns nsns The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

  4. CAPTURESafety results summary Safety endpoint Major TIMI bleedingMinor TIMI bleedingPlatelet count< 100,000/mm3 Placebo(n=635) 1.9%2.0%1.3% Abciximab(n=630) 3.8%4.8%5.6% The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.

More Related